

7. Internationales
7. Symposium

URO ONKO LOGIE



PROGRAM

06. - 07.12.2024
Maritim Hotel Magdeburg

www.isuo.eu

INTERCOM

DIE VERANSTALTUNGSAGENTUR

in Zusammenarbeit mit den wissenschaftlichen Partnern / in cooperation with the scientific partners



MEDIZINISCHE FAKULTÄT



UNIKLINIK
KÖLN



Center for Integrated Oncology
Aachen Bonn Cologne Duesseldorf



WELCOME

Dear Colleagues,

We are delighted to invite you to the 7th edition of the International Symposium on Urological Oncology (ISUO 2024), which will be held in Magdeburg on December 6-7, 2024. This biennial event alternates between Cologne and Magdeburg.

This year's symposium will cover the most critical topics in urological tumors through a comprehensive program that includes case discussions, pro and con debates, panel discussions, state-of-the-art lectures, semi-live videos, and much more. Esteemed national and international speakers will thoroughly discuss these topics. We have selected issues related to surgery, radiotherapy, and pharmacotherapy that are most significant in the current practice of treating urological tumors.

The symposium will be conducted in a hybrid format and will be bilingual with simultaneous translation, ensuring that you can follow all the information without any loss.

We look forward to your active participation, fruitful discussions, and, of course, the opportunity to reconnect with the uro-oncology community in person.

With best regards,


Yours sincerely,

Prof. Dr. med. Martin Schostak

Director of the Clinic for Urology,
Uro-Oncology, Robot-assisted and Focal Therapy,
University Hospital Magdeburg

Prof. Dr. med. Dr. h.c Axel Heidenreich

Director of the Clinic for Urology, Uro-Oncology,
Special Urological and robot-assisted surgery,
University Hospital Cologne



Organizer

Intercom Dresden GmbH | Zellescher Weg 3 | 01069 Dresden
in cooperation with the scientific direction of

Prof. Dr. med. Martin Schostak

Department of Urology, Uro-Oncology, Robot-Assisted and Focal Therapy,
University Hospital, Otto-von-Guericke-University, Magdeburg, Germany

Prof. Dr. med. Dr. h.c Axel Heidenreich

Director of the Department of Urology, Uro-Oncology,
and Special Urological and Robot-Assisted Surgery, University Hospital Cologne

Main Topics

Prostate Cancer:

active surveillance, innovative treatment options in organ confined and locally advanced prostate cancer,
radionuclid and targeted treatment options

Urothelial Cancer:

immuno-oncological treatment concepts, role of radical cystectomy in the management of muscle invasive
disease, SEMI LIVE surgery on urinary diversions, management of upper urinary tract cancer

Renal Cancer:

organ preserving surgical and non-surgical treatment options, cytoreductive nephrectomy, retroperitoneal
lymph node dissection

Testis Cancer/Penile Cancer:

state-of-the Art guidelines recommended treatment options

Event Location

Maritim Hotel Magdeburg | Otto-von-Guericke-Straße 87 | 39104 Magdeburg



Participation Fee

Attendance at the event*		(¹ from 01.10.24)
Specialist physician	285,00 € early bird	305,00 € regular ¹
Junior physician	160,00 € early bird	190,00 € regular ¹
Student	Free of charge (with verification)	
University hospital employee (Urology) Cologne and Magdeburg	Free of charge (with verification)	
Virtual*		
Specialist physician	175,00 € early bird	205,00 € regular ¹
Junior physician	105,00€ early bird	125,00 € regular ¹
Student (m/w/d)	Free of charge (with verification)	
University hospital employee (Urology) Cologne and Magdeburg	Free of charge (with verification)	

Event times (Subject to change!)

Friday	06.12.2024	08:30 - 18:10
Saturday	07.12.2024	08:30 - 14:00

Registration

www.isuo.eu/2024/registration


Certification:

Certification is applied for at the responsible state medical association.

Organisation industrial exhibition

Intercom Dresden GmbH | Christian Nitzsche, Katharina Henze
Zellescher Weg 3, 01069 Dresden | **Phone:** +49 351 320173 -30/-70 | **E-Mail:** isuo@intercom.de

* Intercom Dresden GmbH is the organiser. All registration fees are per person, including 19% VAT, collected in the name and for the account of Intercom Dresden GmbH, Zellescher Weg 3, 01069 Dresden, Germany, UST-ID Nr.: DE 186530195 | This event is supported by industry sponsorship. This sponsorship will be used exclusively for the financing of the following conference services: Participant administration, organisational costs, speaker's fee, printed material, rental costs for event rooms, rental costs for presentation technology as well as for appropriate refreshments during breaks.



FRIDAY, DECEMBER 6, 2024

08:45 OPENING

M. Schostak, Magdeburg, DE

**08:50 PROSTATE CANCER 1
Modern Screening and Staging**

Moderation: M. Schostak, Magdeburg, DE | A. Borkowetz, Rostock, DE

08:50 State-of-the-Art: Biomarkers in early Detection

A. Borkowetz, Rostock, DE

09:03 Hot Topics: Techniques in comparison

09:03 bpMRI vs. mpMRI

T. Franiel, Jena, DE

09:15 mpMRI vs. ExactVu

L. Klotz, Toronto, CA

09:27 Very Hot Topic: transrectal vs. transperitoneal biopsy

D. Pfister, Köln, DE

09:41 State-of-the-Art: Strengths & Weakness of PSMA-PET/CT

M. Eiber, München, DE

09:54 State-of-the-Art: Genetic Diagnostics

K. Riehm, Köln, DE

10:07 BREAK

**10:30 UROTHELIAL CARCINOMA 1
Urinary bladder locally limited**

Moderation: J. Schittko, Magdeburg, DE | B. Osmonov, Lübeck, DE

10:30 Case presentation: pT1 HG pL0 pV0, 2.4cm, no pTis

F. Seelemeyer, Köln, DE

10:32 MRI instead of (re-)TUR

10:32 The New MRI-Pathway

J. Fütterer, Nijmegen, NL

10:42 TUR is indispensable

J. Gschwend, München, DE

10:52 Discussion

10:57 State-of-the-Art: Best Imaging for Bladder Cancer

J. Fütterer, Nijmegen, NL

11:10 State-of-the-Art: Extended Lymphadenectomy in Radical Cystectomy

J. Gschwend, München, DE

11:23 Hot Topic: Radical cystectomy - impact of centres


M. Schrader, Berlin, DE

11:35 State-of-the-Art: New Intravesical Therapies

C. Rieger, Köln, DE



11:48	PROSTATE CANCER 2 Focal Therapy <i>Moderation: M. Schostak, Magdeburg, DE L. Klotz, Toronto, CA</i>
11:48	State-of-the-Art: Focal Therapy - Status 2024 <i>L. Klotz, Toronto, CA</i>
12:01	Semi-Live
12:01	HIFU <i>A. Fehr, Magdeburg, DE</i>
12:11	IRE: <i>F. Colletini, Berlin, DE</i>
12:21	TULSA-PRO <i>L. Halbe, Köln, DE</i>
12:31	Laserablation <i>S. Blaschke, Magdeburg, DE</i>
12:41	Focal HDR-Brachytherapy <i>F. Fischbach, Magdeburg, DE</i>
12:51	LUNCH BREAK
13:40	UROTHELIAL CARCINOMA 2 Local advanced <i>Moderation: P. Paffenholz, Köln, DE A. Stenzl, Stuttgart, DE</i>
13:40	Case Presentation: MIBC cT3 Cn0 cMO <i>M. Lehmann, Köln, DE</i>
13:42	Hot Topic: Neoadjuvant Standard Gem/Cis or ddMVAC ? <i>P. Iwany, Hannover, DE</i>
13:54	State-of-the-Art: adj: Immunotherapy – ready for Prime-Time? <i>A. Lorch, Zürich, CH</i>
14:19	SATELLITE SYMPOSIUM 1: UROTHELIAL CANCER <i>Astellas Pharma GmbH</i>
15:05	UROTHELIAL CARCINOMA 3 Urinary bladder locally limited <i>Moderation: R. Weiten, Köln, DE U.-B. Liehr, Magdeburg, DE</i>
15:05	Case Presentation: High-Grade MIBC in a very young man <i>F. Wallstab, Magdeburg, DE</i>
15:07	Paneldiscussion:
15:07	Radical Surgery (+neoadj. Therapy) <i>B. Osmonov, Lübeck, DE</i>
15:15	Trimodal therapy, radiation + immunotherapy <i>O. Ott, Erlangen, DE</i>
15:23	Partial Resection + Lymphadenectomy <i>P. Nuhn, Kiel, DE</i>
15:31	Discussion
15:39	State-of-the-Art: Sexual function preserving Procedures in Women <i>A. Stenzl, Stuttgart, DE</i>
15:52	BREAK



PROGRAM DAY 1

16:20 PROSTATE CANCER 3

Organ confined

Moderation: F. Seseke, Halle, DE | L. Klotz, Toronto, CA

16:20 Case Presentation: PSA-Density >0,3; PIRADS 5

J. Vogt, Magdeburg, DE

16:22 Pro-und-Con: Therapy without Biopsy?

16:22 Pro (Biopsy is dispensable)

M. Chaloupka, München, DE

16:32 Con (Biopsy is necessary)

A. Blana, Fürth, DE

16:42 Discussion

16:47 Case Presentation: ISUP 2, PSA 14.3 ng/ml, 4/4 Index positive, Vol. 162 ml

O. Steenbock, Köln, DE

16:49 Paneldiscussion

16:49 Radical Prostatectomy

F. Wawrochek, Oldenburg, DE

16:57 Laserenucleation + HIFU or AS

H. Cash, Berlin, DE

17:05 Discussion

17:13 SATELLITE SYMPOSIUM 2: PROSTATE CANCER 2

Novartis Pharma GmbH

17:58 UROTHELIAL CANCER 4

Utuc

Moderation: F. Wawrochek, Oldenburg, DE | F. Seseke, Halle, DE

17:58 Case Presentation: Z.n. RCX, GFR 80, now 2 cm HG UTUC

K. Al-Assali, Magdeburg, DE

18:00 Paneldiscussion

18:00 Nephroureterectomy

M. Pallauf, Salzburg, AT

18:10 Organ preserving approach

U.-B. Liehr, Magdeburg, DE

18:20 Discussion

18:28 PENILE CANCER

Moderation: F. Wawrochek, Oldenburg, DE | F. Seseke, Halle, DE

18:28 State-of-the-Art: Second Line Therapy

B. Ayres, London, UK

18:41 PROSTATE CANCER 4


Metastatic Prostate Cancer

Moderation: A. Heidenreich, Köln, DE | M. Schostak, Magdeburg, DE

18:41 Hot Topic: SPARC Consensus on Lutetium-Response

A. Bjartell, Malmö, SE

18:53 END OF DAY 1



SATURDAY, DECEMBER 7, 2024

08:15 OPENING

M. Schostak, Magdeburg, DE

08:20 RENAL CANCER 1

Modern Staging

Moderation: J. Bedtke, Stuttgart, DE | T. Klatter, Bad Saarow, DE

08:20 Hot Topics:

08:20 When do we need a biopsy?

H. Reis, Frankfurt/Main, DE

08:32 New imaging for cystic tumors

A. Hötter, Zürich, CH

08:44 Localized disease

08:44 Hot Topics: „Partial Nephrectomy – always Off-Clamp and (almost) always organ-preserving !“

G. Simone, Rom, IT

08:56 SATELLITE SYMPOSIUM 3: KIDNEY CANCER

Ipsen Pharma GmbH

09:41 BREAK

10:05 PROSTATE CANCER 5

Lymphadenectomy

Moderation: G. Simone, Rom, IT | A. Blana, Fürth, DE

10:05 Case presentation: PSA 9 ng/ml, cT1c, ISUP 2 (52% Cores with High Grade)

J. Heidenreich, Köln, DE

10:07 Pro und Con: Bury Lymph adenectomy

10:07 Pro (No Lymphadenectomy)

D. Tilki, Hamburg, DE

10:17 Contra (Lymphadenectomy !)

A. Heidenreich, Köln, DE

10:27 Discussion

10:32 State-of-the-Art: New Standards in Radiation for High Risk PCA

U. Ganswindt, Innsbruck, AT

10:45 Recurrence

10:45 Case presentation: High Risk biochem. Rezidiv, neg.PSMA-PET/CT

J. Seifert, Magdeburg, DE

10:47 Paneldiscussion

10:47 Radiation + ADT

N.-S. Schmidt-Hegemann, München, DE

10:55 Systemic Treatment alone

M. Schostak, Magdeburg, DE

11:03 Guideline View and Conclusion

D. Tilki, Hamburg, DE

11:11 Discussion



11:19 RENAL CANCER 2

Locally advanced / metastatic

Moderation: P. Paffenholz, Köln, DE | G. Gakis, Halle, DE

11:19 State-of-the-Art: Lymphadenectomy at High Risk RCC?!

S. Siemer, Homburg, DE

11:32 Case presentation: Oligometastatic RCC

B. Ahmad, Magdeburg, DE

11:35 Paneldiscussion

11:35 New Imaging

A. Hötker, Zürich, CH

11:43 Metasectomy/ablation

T. Klatter, Bad Saarow, DE

11:51 Stereotactic Radiation Therapy

U. Ganswindt, Innsbruck, AT

11:59 cytoreduktive Nephrectomy

J. Bedke, Stuttgart, DE

12:07 Discussion

12:15 SATELLITE SYMPOSIUM 4: KIDNEY CANCER

Bristol-Myers Squibb GmbH & Co. KGaA

13:00 LUNCH BREAK

13:45 SEMI-LIVE PROSTATE CANCER

Prostate Cancer - RALP – different approaches in comparison

Moderation: D. Pfister, Köln, DE / D. Tilki, Hamburg, DE

13:45 Transperitoneal Approach

J. Witt, Düsseldorf, DE

13:55 Retzius-sparing Approach

K. Fransis, Antwerpen, BE

PENILE AND TESTICULAR CANCER

Moderation: D. Pfister, Köln, DE / D. Tilki, Hamburg, DE

14:05 Inguinal Sentinel- Lymphadenectomy

B. Ayres, London, UK

14:15 URETHRAL CANCER

Moderation: D. Pfister, Köln, DE / D. Tilki, Hamburg, DE

14:15 State-of-the-Art: Diagnostics & Therapy

G. Gakis, Halle, DE

14:28 CONCLUSION AND OUTLOOK FOR 2025

A. Heidenreich, Köln, DE

14:33 END OF DAY 2: